Aerosoling Phages? We've got you covered.
Download PDF here
Assessment of Nebulizer Performance for Aerosolization of Bacteriophages
As interest in inhaled phage therapy continues to grow, understanding how nebulization affects phage stability and aerosol output is becoming increasingly important. At JAFRAL, we have established robust workflows to evaluate phage behaviour during different types of nebulization.
Respirable fraction
45–60% of phage particles were delivered in the <5.4 µm range, suitable for lower airway deposition.
Consistent aerosol properties
Aerosols showed an MMAD of ~4.2 µm, aligning with pulmonary delivery requirements.
Formulation stability
Tested phage buffers exhibited no visible aggregation or instability during nebulization.
Our methods help teams assess the performance of their phages during nebulization, compare device behaviour, and evaluate formulation suitability for inhaled delivery.
For more detailed data and methodology, download the full PDF.
